MSH6-T1142M was previously suggested to be probably pathogenic based on clinical data describing the variant in a 27 year old patient with polyps who met the Bethesda guidelines, had a 61 year old mother with polyps, and did not carry pathogenic mutations in any other MMR gene nor showed MLH1 promoter methylation in the tumor [36]. This evidence concerns the gene MLH1 and neoplasm.